Calciphylaxis or uremic arteriolopathy is a complex process typically seen in patients with end-stage renal disease, but has also been reported in patients with normal renal function. However, therapies for calciphylaxis are based on reports of traditional patients (i.e., end-stage renal disease). A mainstay of therapy, sodium thiosulfate (STS), has been shown to be effective for the treatment of calciphylaxis. Without a standardized therapy reported for nondialysis patients there is a need for evidence-based therapy. Here, we report a case of a 63-year-old woman with an acute injury on chronic kidney disease (CrClBaseline = 48 mL/min, CrClAKI = 36 mL/min), not requiring dialysis, with warfarin-induced calciphylaxis. After 4 weeks of therapy with STS, sevelamer, alendronate, and enzymatic debridement the patient subjectively reported slight improvement of the necrotic ulcers but developed cellulitis on her nonaffected limb. Additionally, after 12 weeks of therapy she was readmitted for renal failure and subsequently required dialysis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714392 | PMC |
http://dx.doi.org/10.4103/0976-500X.171882 | DOI Listing |
Saprolegniasis is one of the most dangerous fungal diseases of fish, causing significant mortality in fish hatcheries and young ones. The present study aimed to isolate and characterize the causative fungus from fingerlings of Pangasianodon hypophthalmus cultured intensively in freshwater cages in Indian reservoirs and to determine minimum inhibitory concentrations of different antifungal compounds against the fungal hyphae and zoospores. The fungal isolates grown on potato dextrose agar showed an abundance of gemmae, elongated mycelia, non-septate hyphae, primary zoospores, mature zoosporangia with numerous zoospores, cysts with bundles of long hairs and were further identified as Saprolegnia parasitica following PCR amplification and sequencing of internal transcribed spacer region.
View Article and Find Full Text PDFSci Rep
December 2024
Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, M13 9PT, UK.
Calcinosis cutis affects 20-40% of patients with systemic sclerosis. This study tests the hypothesis that calcium-chelating polycarboxylic acids can induce calcium dissolution without skin toxicity or irritancy. We compared citric acid (CA) and ethylenediaminetetraacetic acid (EDTA) to sodium thiosulfate (STS) for their ability to chelate calcium in vitro using a pharmaceutical dissolution model of calcinosis (hydroxyapatite (HAp) tablet), prior to evaluation of toxicity and irritancy in 2D in vitro skin models.
View Article and Find Full Text PDFJBMR Plus
January 2025
Department of Orthopedic Surgery, Tokyo Women's Medical University, Tokyo, 162-8666, Japan.
Calciphylaxis, also known as calcific uremic arteriolopathy (CUA), is a rare disorder with many unknown treatment and diagnostic aspects. It is characterized by calcification and thrombosis of small blood vessels. This disease leads to progressive skin calcification, necrotizing ulcers, and infections and is associated with a high mortality rate.
View Article and Find Full Text PDFExpert Opin Drug Saf
December 2024
Bahrain Defence Force Royal Medical Services, Riffa, Kingdom of Bahrain.
Background: Calciphylaxis is a serious, potentially fatal condition resulting in pathological calcification of soft tissues. While associated with chronic kidney disease, data regarding anticoagulant involvement remain limited.
Research Design And Methods: The United States Food and Drug Administration Adverse Event Reporting System (USFDA AERS) database was searched to identify calciphylaxis reports linked to anticoagulants from 2004 to 2024.
Pediatr Blood Cancer
December 2024
Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, California, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!